Gold standards in pharmacovigilance - The use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore

被引:50
作者
Hauben, Manfred [1 ]
Aronson, Jeffrey K.
机构
[1] Pfizer Inc, New York, NY 10017 USA
[2] NYU, Sch Med, Dept Med, New York, NY USA
[3] New York Med Coll, Metropolitan Hosp Ctr, Dept Community & Prevent Med, Valhalla, NY 10029 USA
[4] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA
[5] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
关键词
D O I
10.2165/00002018-200730080-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Anecdotal reports of adverse drug reactions are generally regarded as being of poor evidential quality. This is especially relevant for postmarketing drug safety surveillance, which relies heavily on spontaneous anecdotal reports. The numerous limitations of spontaneous reports cannot be overemphasised, but there is another side to the story: these datasets also contain anecdotal reports that can be considered to describe definitive adverse reactions, without the need for further formal verification. We have previously defined four categories of such adverse reactions: (i) extracellular or intracellular tissue deposition of the drug or a metabolite; 00 a specific anatomical location or pattern of injury; (iii) physiological dysfunction or direct tissue damage demonstrable by physicochemical testing; and (iv) infection, as a result of the administration of an infective agent as the therapeutic substance or because of demonstrable contamination. In this article, we discuss the implications of these definitive ('between-the-eyes') adverse effects for pharmacovigilance.
引用
收藏
页码:645 / 655
页数:11
相关论文
共 89 条
  • [1] Risk management of extravasation of cytostatic drugs at the Adult Chemotherapy Outpatient Clinic of a university hospital
    Adami, NP
    de Gutiérrez, MGR
    da Fonseca, SM
    de Almeida, EPM
    [J]. JOURNAL OF CLINICAL NURSING, 2005, 14 (07) : 876 - 882
  • [2] AMIODARONE AND ITS DESETHYL METABOLITE - TISSUE DISTRIBUTION AND MORPHOLOGIC CHANGES DURING LONG-TERM THERAPY
    ADAMS, PC
    HOLT, DW
    STOREY, GCA
    MORLEY, AR
    CALLAGHAN, J
    CAMPBELL, RWF
    [J]. CIRCULATION, 1985, 72 (05) : 1064 - 1075
  • [3] EXPERIMENTAL ANIMAL STUDIES ON EMBOLIA CUTIS MEDICAMENTOSA
    ALBRECHT, KH
    LITTMANN, K
    RICHTER, HJ
    EIGLER, FW
    [J]. LANGENBECKS ARCHIV FUR CHIRURGIE, 1984, 362 (01): : 17 - 23
  • [4] Intrathecal vincristine: Fatal myeloencephalopathy despite cerebrospinal fluid perfusion
    Alcaraz, A
    Rey, C
    Concha, A
    Medina, A
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2002, 40 (05): : 557 - 561
  • [5] Drug safety - Anecdotes that provide definitive evidence
    Aronson, Jeffrey K.
    Hauben, Manfred
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 333 (7581): : 1267 - 1269
  • [6] Clarification of terminology in drug safety
    Aronson, JK
    Ferner, RE
    [J]. DRUG SAFETY, 2005, 28 (10) : 851 - 870
  • [7] Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions
    Aronson, JK
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2005, 11 (02) : 195 - 208
  • [8] Lipoid pneumonia: A silent complication of mineral oil aspiration
    Bandla, HPR
    Davis, SH
    Hopkins, NE
    [J]. PEDIATRICS, 1999, 103 (02) : art. no. - e19
  • [9] Comparing data mining methods on the VAERS database
    Banks, D
    Woo, EJ
    Burwen, DR
    Perucci, P
    Braun, MM
    Ball, R
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (09) : 601 - 609
  • [10] Barclay TS, 2002, ANN PHARMACOTHER, V36, P1558